Targeted therapy for advanced anaplastic lymphoma kinase (<i>ALK</i> )-rearranged non-small cell lung cancer-Reference-Cited by-同舟云学术

Targeted therapy for advanced anaplastic lymphoma kinase (ALK )-rearranged non-small cell lung cancer

Published:2022-01-07 Issue:1 Volume:2022 Page:
ISSN:1465-1858
Container-title:Cochrane Database of Systematic Reviews
language:en
Short-container-title:

Author:

Cameron Laird B¹,Hitchen Nadia¹,Chandran Elias¹,Morris Tessa²³,Manser Renée⁴⁵⁶,Solomon Benjamin J⁷,Jordan Vanessa⁸

Affiliation:

1. Department of Medical Oncology "Te Puriri o Te Ora"; Auckland District Health Board; Auckland New Zealand

2. Southern Blood and Cancer Service; Southern District Healthboard; Dunedin New Zealand

3. Department of Medicine; University of Otago; Dunedin New Zealand

4. Department of Haematology and Medical Oncology; Peter MacCallum Cancer Centre; Melbourne Australia

5. Department of Respiratory and Sleep Medicine; Royal Melbourne Hospital; Parkville Australia

6. Department of Medicine; Royal Melbourne Hospital, The University of Melbourne; Parkville Australia

7. Department of Medical Oncology; Peter MacCallum Cancer Centre; Melbourne Australia

8. Department of Obstetrics and Gynaecology, Faculty of Medical and Health Sciences; The University of Auckland; Auckland New Zealand

Publisher

Wiley

Subject

Pharmacology (medical)

Reference220 articles.

1. A study to evaluate and compare the efficacy and safety of alectinib versus crizotinib and to evaluate the pharmacokinetics of alectinib in Asian participants with treatment-naive anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) clinicaltrials.gov/ct2/show/NCT02838420

2. Alectinib versus crizotinib in untreated Asian patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALESIA): a randomised phase 3 study;Zhou;Lancet,2019

3. Primary results of ALESIA: a randomised, phase III, open-label study of alectinib vs crizotinib in Asian patients with treatment-naive ALK1 advanced NSCLC;Zhou;Annals of Oncology,2018

4. Primary results of ALESIA: phase III, randomised open label study of alectinib (ALC) vs crizotinib (CRZ) in Asian patients (pts) with treatment-naive ALK+ advanced non-small-cell lung cancer (NSCLC);Zhou;Annals of Oncology,2018

5. Updated efficacy and safety data and impact of the EML4-ALK fusion variant on the efficacy of alectinib in untreated ALK-positive advanced non-small cell lung cancer in the global phase III ALEX study;Camidge;Journal of Thoracic Oncology,2019

Cited by 35 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. New findings on the incidence and management of CNS adverse reactions in ALK-positive NSCLC with lorlatinib treatment;Discover Oncology;2024-09-13

2. Neurocognitive Adverse Events Related to Lorlatinib in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis;Cancers;2024-07-22

3. Brigatinib in ALK-Positive ALCL after Failure of Brentuximab Vedotin;New England Journal of Medicine;2024-06-13

4. Downregulation of DIP2B as a prognostic marker inhibited cancer proliferation and migration and was associated with immune infiltration in lung adenocarcinoma via CCND1 and MMP2;Heliyon;2024-06

5. A multicenter, retrospective archive study of radiological and clinical features of ALK-positive non-small cell lung cancer patients and crizotinib efficacy;Medicine;2024-05-24